/TRAW
TRAW Stock - Traws Pharma, Inc.
Healthcare|BiotechnologyNASDAQ
$1.27+2.00%
+$0.03 (+2.00%) • Dec 19
60
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.19
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.50
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+527.5%upside
Target: $8.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TRAW
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.26 – $1.29
TARGET (TP)$8.00
STOP LOSS$1.17
RISK/REWARD1:64.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.75
52W High$19.44
52W Low$0.97
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $226,000 | $226,000 | $226,000 | $226,000 | $231,000 |
| Gross Profit | $214,000 | $226,000 | $226,000 | $226,000 | $231,000 |
| Gross Margin | 94.7% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-49,348,000 | $-20,298,000 | $-19,627,000 | $-16,496,000 | $-24,993,000 |
| Net Income | $-54,674,000 | $-18,948,000 | $-18,964,000 | $-16,163,000 | $-25,157,000 |
| Net Margin | -24192.0% | -8384.1% | -8391.2% | -7151.8% | -10890.5% |
| EPS | $-35.21 | $-22.57 | $-22.68 | $-24.01 | $-54.21 |
Company Overview
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$8
Average Target
↑ 527.5% Upside
Now
$8
Low
$8
Average
$8
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 3rd 2025 | H.C. Wainwright | Initiation | Buy | $8 |
Earnings History & Surprises
TRAWBeat Rate
57%
Last 14 quarters
Avg Surprise
-415.2%
EPS vs Estimate
Beats / Misses
8/5
1 met exactly
Latest EPS
$-0.34
Q4 2025
EPS Surprise History
Q4 23
+11.5%
$-0.23vs$-0.26
Q2 24
+24.0%
$-0.19vs$-0.25
Q2 24
0.0%
$-6.00vs$-6.00
Q3 24
-1848.0%
$-121.75vs$-6.25
Q4 24
-44.0%
$-8.81vs$-6.12
Q1 25
+1101.7%
$95.66vs$-9.55
Q3 25
+98.7%
$-0.11vs$-8.75
Q4 25
+96.3%
$-0.34vs$-9.16
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-1.91 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-9.16 | $-0.34 | +96.3% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-8.75 | $-0.11 | +98.7% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-9.55 | $95.66 | +1101.7% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-6.12 | $-8.81 | -44.0% | ✗ MISS |
Q3 2024 | Aug 15, 2024 | $-6.25 | $-121.75 | -1848.0% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-6.00 | $-6.00 | 0.0% | = MET |
Q2 2024 | Apr 1, 2024 | $-0.25 | $-0.19 | +24.0% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.26 | $-0.23 | +11.5% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-7.81 | $-5.00 | +36.0% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $-7.44 | $-11.95 | -60.6% | ✗ MISS |
Q1 2023 | Mar 16, 2023 | $-6.94 | $-6.50 | +6.3% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | $-5.31 | $-12.92 | -143.3% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.20 | $-0.19 | +3.8% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | $-0.19 | $-9.74 | -5095.8% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | — | $-8.63 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-14.17 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-25.55 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-27.62 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-34.89 | — | — |
Latest News
Traws Pharma's Interim Data For Ratutrelvir Demonstrated A Differentiated Clinical Profile In Pre-specified Interim Analysis Of An Ongoing Open-label Phase 2 Study For Mild-to-moderate Covid-19, Final Data Analysis Expected In January 2026
📈 PositiveBenzinga•Dec 17, 2025, 11:02 AM
HC Wainwright & Co. Initiates Coverage On Traws Pharma with Buy Rating, Announces Price Target of $8
📈 PositiveBenzinga•Dec 3, 2025, 12:00 PM
Traws Pharma Q3 EPS $(0.34) Up From $(8.81) YoY
📈 PositiveBenzinga•Nov 13, 2025, 12:17 PM
Reported Earlier, Traws Pharma Ratutrelvir Demonstrates Broad-Spectrum Activity Against SARS-CoV-2 Without Ritonavir Enabling Treatment Of PAXLOVID-Ineligible Patients And Prevention Of Viral Rebound
📈 PositiveBenzinga•Oct 23, 2025, 07:14 AM
Traws Pharma Doses First Patient With Ratutrelvir In Phase 2 COVID Studies, Expects Top-Line Data By Year-End 2025
📈 PositiveBenzinga•Oct 14, 2025, 11:07 AM
On September 9, Traws Pharma Enters Asset Purchase Agreement With Virom; Purchases Assets From Virom For $2.35M In Cash
📈 PositiveBenzinga•Sep 12, 2025, 08:38 PM
Traws Pharma Receives HREC Approval To Initiate Phase 2 COVID Studies Of Ratutrelvir, A Ritonavir-Free Treatment, With Results Expected By Year-End 2025
📈 PositiveBenzinga•Aug 18, 2025, 11:08 AM
Traws Pharma Posts Q2 Revenue Jump
📈 PositiveThe Motley Fool•Aug 14, 2025, 11:15 AM
Frequently Asked Questions about TRAW
What is TRAW's current stock price?
Traws Pharma, Inc. (TRAW) is currently trading at $1.27 per share. The stock has moved +2.00% today.
What is the analyst price target for TRAW?
The average analyst price target for TRAW is $8.00, based on 1 analyst.
What sector is Traws Pharma, Inc. in?
Traws Pharma, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TRAW's market cap?
Traws Pharma, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does TRAW pay dividends?
No, Traws Pharma, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBOLT
Bolt Biotherapeutics, Inc.
$5.16
Mkt Cap: $0.0B
BRTX
BioRestorative Therapies, Inc.
$1.15
Mkt Cap: $0.0B
CING
Cingulate Inc.
$3.97
Mkt Cap: $0.0B
COCP
Cocrystal Pharma, Inc.
$0.99
Mkt Cap: $0.0B
DWTX
Dogwood Therapeutics, Inc.
$6.45
Mkt Cap: $0.0B
EVGN
Evogene Ltd.
$1.02
Mkt Cap: $0.0B
IMNN
Imunon, Inc.
$3.75
Mkt Cap: $0.0B
IMRN
Immuron Limited
$0.94
Mkt Cap: $0.0B
MBIO
Mustang Bio, Inc.
$1.09
Mkt Cap: $0.0B
SNSE
Sensei Biotherapeutics, Inc.
$8.86
Mkt Cap: $0.0B
Explore stocks similar to TRAW for comparison